DR. JAYESH B. GOSAI M.D. NPI 1841253937

NPI Details

DR. Jayesh B. Gosai, M.D. is an internal medicine in Rices Landing, PA with 39 years of experience. The provider is a physician who provides long-term, comprehensive care in the office and the hospital, managing both common and complex illness of adolescents, adults and the elderly. Internists are trained in the diagnosis and treatment of cancer, infections and diseases affecting the heart, blood, kidneys, joints and digestive, respiratory and vascular systems. They are also trained in the essentials of primary care internal medicine, which incorporates an understanding of disease prevention, wellness, substance abuse, mental health and effective treatment of common problems of the eyes, ears, skin, nervous system and reproductive organs. DR. Jayesh B. Gosai, M.D. NPI is 1841253937. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

1895 JEFFERSON RD
RICES LANDING, PA
ZIP 15357-165
Phone: (724) 883-2223
Fax: (724) 883-3300

The NPI 1841253937 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, ceftriaxone sodium, per 250 mg (HCPCS:J0696)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Intravenous injection, bebtelovimab, includes injection and post administration monitoring (HCPCS:M0222)
• Injection, bebtelovimab, 175 mg (HCPCS:Q0222)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Injection, ketorolac tromethamine, per 15 mg (HCPCS:J1885)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of drug or substance into vein (HCPCS:96374)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Measurement of neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (covid-19) (HCPCS:86409)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring (HCPCS:M0245)
• Injection, bamlanivimab and etesevimab, 2100 mg (HCPCS:Q0245)
• Intravenous infusion, sotrovimab, includes infusion and post administration monitoring (HCPCS:M0247)
• Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected (HCPCS:0241U)
• Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique (HCPCS:87581)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes (HCPCS:G0446)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Influenza vaccine, quadrivalent, 0.5 ml dosage (HCPCS:90688)
• Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit (HCPCS:G0439)
• Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets (HCPCS:87631)
• Ultrasound of heart with color-depicted blood flow, rate, direction and valve function (HCPCS:93306)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen (HCPCS:87635)
• Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring (HCPCS:M0243)
• Injection, casirivimab and imdevimab, 2400 mg (HCPCS:Q0243)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Face-to-face behavioral counseling for obesity, 15 minutes (HCPCS:G0447)
• Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report (HCPCS:93000)
• Injection, methylprednisolone acetate, 40 mg (HCPCS:J1030)
• Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous (HCPCS:G0328)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• New patient office or other outpatient visit, 15-29 minutes (HCPCS:99202)
• Prostate cancer screening; prostate specific antigen test (psa) (HCPCS:G0103)
• Annual depression screening, 15 minutes (HCPCS:G0444)
• Melanoma (skin cancer) excision (HCPCS:NAN03)

The enumeration date for this NPI number is 4/10/2006 and was last updated on 5/1/2008.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.